Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
12 pending office actions • 8 art units • 11 examiners • 0 of 12 (0%) have an AI response strategy ready • 19 patents granted in the last 365 days
Chiesi Farmaceutici S.p.a. maintains a portfolio with 11 pending office actions in the Biotechnology & Pharmaceuticals technology area. Prosecution is highly distributed among 10 distinct examiners. This breadth of personnel is matched by a wide technical range, as the actions are spread across 7 distinct art units.
The busiest examiner, ENGLISH, CONNOR KENNEDY, is currently handling 2 pending office actions. The other actions are divided among the remaining distinct examiners. Such a diverse distribution across many art units suggests that the company is pursuing a broad array of pharmaceutical innovations. Practitioners must adapt to various examiner styles and art unit specificities, as the high count of distinct examiners limits the ability to apply a single negotiation tactic across the portfolio. The presence of 7 different art units further complicates the landscape, requiring specialized knowledge of multiple USPTO divisions to ensure consistent results.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (8%) |
| §101 + other | 1 (8%) |
| §103 only | 2 (17%) |
| §112 only | 4 (33%) |
| Double-patenting + other | 2 (17%) |
| Multi-statute (no §101) | 2 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ENGLISH, CONNOR KENNEDY | 2 | 60.0% | +51.3% |
| SEAMAN, D MARGARET M | 1 | 76.5% | +8.0% |
| YOUNGBLOOD, WILLIAM JUSTIN | 1 | 60.0% | +41.7% |
| ISLAM, MOHAMMAD K | 1 | 82.9% | +17.2% |
| ARNOLD, ERNST V | 1 | 48.2% | +12.9% |
| NOTTINGHAM, KYLE GREGORY | 1 | 61.7% | +31.9% |
| GONZALEZ, LUISALBERTO | 1 | 59.4% | +47.2% |
| LEE, CHIHYI NMN | 1 | 33.7% | +60.8% |
| MEYERS, ELIZABETH ANNE | 1 | 23.5% | +92.9% |
| BASQUILL, SEAN M | 1 | 38.8% | +21.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18282068 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | LEE, CHIHYI NMN | 26d |
| 18885921 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PRODUCING LOW IMPURITY CONCENTRATIONS OF THE SAME | SEAMAN, D MARGARET M | — |
| 18844467 | AMIDO CYCLOPROPYL DERIVATIVES AS LPA RECEPTOR INHIBITORS | YOUNGBLOOD, WILLIAM JUSTIN | — |
| 18704036 | APPARATUS FOR ADMINISTERING MEDICAMENTS AND METHOD FOR MANAGING EXPIRY DATES OF A MEDICAMENT DISPENSER | ISLAM, MOHAMMAD K | — |
| 18203381 | Pharmaceutical Compositions and Methods for Stabilizing the Same | MEYERS, ELIZABETH ANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18283855 | INDOLINE DERIVATIVES AS DDR1 AND DDR2 INHIBITORS | NOTTINGHAM, KYLE GREGORY | 5d |
| 18282068 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | LEE, CHIHYI NMN | 26d |
| 18631588 | CLEVIDIPINE EMULSION FORMULATIONS CONTAINING ANTIMICROBIAL AGENTS | ARNOLD, ERNST V | 30d |
| 18551942 | 8-CYCLO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | GONZALEZ, LUISALBERTO | 48d |
| 18859618 | NEW CRYSTAL FORM OF A PDE4 INHIBITOR | ENGLISH, CONNOR KENNEDY | — |
| 18844467 | AMIDO CYCLOPROPYL DERIVATIVES AS LPA RECEPTOR INHIBITORS | YOUNGBLOOD, WILLIAM JUSTIN | — |
| 18728106 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | ENGLISH, CONNOR KENNEDY | — |
| 18704036 | APPARATUS FOR ADMINISTERING MEDICAMENTS AND METHOD FOR MANAGING EXPIRY DATES OF A MEDICAMENT DISPENSER | ISLAM, MOHAMMAD K | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| 1613 | 1 |
| 1621 | 1 |
| 1624 | 1 |
| 1628 | 1 |
| 1622 | 1 |
| 1614 | 1 |
| 3785 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18859618 | NEW CRYSTAL FORM OF A PDE4 INHIBITOR | ENGLISH, CONNOR KENNEDY | 1629 | §112 | Non-Final OA | — | Pending | Oct 24, 2024 |
| 18885921 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PRODUCING LOW IMPURITY CONCENTRATIONS OF THE SAME | SEAMAN, D MARGARET M | — | §101§102§112 | Non-Final OA | — | Pending | Sep 16, 2024 |
| 18844467 | AMIDO CYCLOPROPYL DERIVATIVES AS LPA RECEPTOR INHIBITORS | YOUNGBLOOD, WILLIAM JUSTIN | — | §102§103 | Non-Final OA | — | Pending | Sep 06, 2024 |
| 18728106 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | ENGLISH, CONNOR KENNEDY | — | §112 | Non-Final OA | — | Pending | Jul 11, 2024 |
| 18704036 | APPARATUS FOR ADMINISTERING MEDICAMENTS AND METHOD FOR MANAGING EXPIRY DATES OF A MEDICAMENT DISPENSER | ISLAM, MOHAMMAD K | — | §101 | Non-Final OA | — | Pending | Apr 23, 2024 |
| 18631588 | CLEVIDIPINE EMULSION FORMULATIONS CONTAINING ANTIMICROBIAL AGENTS | ARNOLD, ERNST V | 1613 | §103DP | Final Rejection | 30d | Pending | Apr 10, 2024 |
| 18283855 | INDOLINE DERIVATIVES AS DDR1 AND DDR2 INHIBITORS | NOTTINGHAM, KYLE GREGORY | 1621 | §112 | Final Rejection | 5d | Pending | Sep 25, 2023 |
| 18551942 | 8-CYCLO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | GONZALEZ, LUISALBERTO | 1624 | §112 | Non-Final OA | 48d | Pending | Sep 22, 2023 |
| 18282068 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | LEE, CHIHYI NMN | 1628 | §102§103§112 | Non-Final OA | 26d | Pending | Sep 14, 2023 |
| 18203381 | Pharmaceutical Compositions and Methods for Stabilizing the Same | MEYERS, ELIZABETH ANNE | 1622 | §112DP | Non-Final OA | — | Pending | May 30, 2023 |
| 18030153 | A PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER | BASQUILL, SEAN M | 1614 | §103Other | Final Rejection | — | Pending | Apr 04, 2023 |
| 17801067 | PRESSURISED METERED DOSE INHALERS COMPRISING A BUFFERED PHARMACEUTICAL FORMULATION | JANG, JAEICK | 3785 | §103 | Final Rejection | 12d | Pending | Aug 19, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial